Skip to search formSkip to main contentSkip to account menu

CNS 1102

Known as: CNS-1102 
National Institutes of Health

Related topics

Related topics

1 relation

Broader (1)

aptiganel

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2010
2010
Caffeinol at the Receptor Level: Anti-Ischemic Effect of N-Methyl-d-Aspartate Receptor Blockade Is Potentiated by Caffeine
Background and Purpose— Although caffeinol (a combination of a low dose of caffeine and ethanol) was shown to robustly reduce… 
2000
2000
Efficacy of a new neuroprotective agent, gacyclidine, in a model of rat spinal cord injury.
Prevention of the immediate excitotoxic phase occurring in response to spinal cord injury (SCI) is a major issue to reduce the… 
1995
1995
Clinical Pharmacology of CNS 1102 in Volunteers
The high affinity noncompetitive N-methyl-D-aspartate receptor antagonist CNS 1102 (aptiganel hydrochloride, Cambridge… 
1995
1995
Systemic and Cerebral Hemodynamic Responses to the Noncompetitive N-Methyl-D-Aspartate (NMDA) Antagonist CNS 1102
The excitatory amino acid antagonists are being developed as neuroprotective drugs aimed at limiting ischemic neuronal damage… 
1994
1994
Delayed Treatment with a Noncompetitive NMDA Antagonist, CNS-1102, Reduces Infarct Size in Rats
The cerebroprotective effects of noncompetitive N-methyl- D -aspartate (NMDA) antagonists are well documented in animal focal… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)